While the PD-L1 antibody could also bind tumor cells for immune checkpoint inhibition for tumor immunotherapy, all the results demonstrated that PHDM+anti-PDL1 was a potential for tumor immune-chemotherapy. This evidence concerns the gene CD274 and neoplasm.